Jeena Sikho Lifecare Limited, a prominent player in the Ayurvedic healthcare sector, has made significant strides in advancing evidence-based Ayurvedic practices with the publication of four pioneering case studies. The research, co-authored by the company's Managing Director Acharya Manish Grover and other medical professionals associated with the firm, focuses on innovative Ayurvedic approaches to liver health, tubal blockage, early-stage Type 2 diabetes, and liver disease management.

Groundbreaking Research in Ayurvedic Medicine

The case studies, which demonstrate the potential of Ayurvedic treatments in addressing complex health issues, include:

1. Restoration of liver health in hepatomegaly with fatty liver
2. Management of tubal blockage
3. Treatment of early-stage Type 2 diabetes mellitus
4. Liver disease management through diet and Panchakarma therapy

These studies showcase the efficacy of Ayurvedic interventions in conditions that are increasingly prevalent in modern society.

Collaborative Effort in Ayurvedic Research

The research team, led by Acharya Manish Grover, included several medical professionals associated with Jeena Sikho Lifecare Limited:

• Dr. Gitika Chaudhary
• Dr. Richa
• Mr. Upam
• Dr. Tanu Rani
• Dr. Shweta
• Dr. Navneet Kaur
• Mr. Siddharth Charan

This collaborative approach underscores the company's commitment to fostering a team of experts dedicated to advancing Ayurvedic science.

Implications for Ayurvedic Practice

The case studies reported positive outcomes across various health conditions:

• Normalized liver function tests in hepatomegaly cases
• Restored tubal patency in fertility-related issues
• Improved markers in early-stage diabetes management
• Effective liver disease management through dietary and therapeutic interventions

These results highlight the potential of Ayurvedic treatments as complementary or alternative approaches to conventional medicine, particularly in chronic and lifestyle-related disorders.

Commitment to Evidence-Based Ayurveda

Acharya Manish Grover, Managing Director of Jeena Sikho Lifecare Limited, emphasized the importance of this research: "These case studies represent our ongoing commitment to advancing Ayurvedic research and promoting evidence-based clinical practices. By documenting and sharing these findings, we aim to contribute to the growing body of scientific literature supporting Ayurvedic interventions."

The publication of these case studies marks a significant step in bridging traditional Ayurvedic knowledge with modern scientific methodology. It also reinforces Jeena Sikho Lifecare Limited's position as a leader in innovative Ayurvedic research and treatment.

As the healthcare community continues to seek integrative approaches to complex health issues, research like this from Jeena Sikho Lifecare Limited paves the way for a more comprehensive understanding of Ayurveda's role in modern medicine. The company's efforts in documenting and sharing these clinical experiences contribute significantly to the field, potentially influencing future research directions and treatment protocols in Ayurvedic medicine.

Jeena Sikho Lifecare Limited has announced a series of significant developments, including receiving regulatory approvals for its Employee Stock Option Scheme and key leadership changes, positioning the company for strategic growth in the healthcare sector.

Stock Exchange Approvals for ESOP Scheme

The company has received crucial in-principle approvals from both major stock exchanges for its Employee Stock Option Scheme 2025. The approvals cover the listing of up to 2,50,000 equity shares of ₹2.00 each under the scheme.

These approvals represent a significant milestone following the Board's initial approval of the ESOP scheme on August 27, 2025. The scheme aims to benefit eligible employees and directors across the company and its group entities.

Leadership Appointments and Changes

The company appointed Sahil Jain as its new Chief Operating Officer, effective August 27, 2025. Jain brings over eight years of experience within the organization, having previously led key departments including IT, Marketing, Call Center Operations, and Administration. His background includes valuable experience at global technology firms IBM and HCL Australia.

In a significant board restructuring, Shreya Grover has been redesignated from Non-Executive Director to Whole-Time Director for a five-year term. Grover, daughter of Managing Director Manish Grover and associated with the company since June 2021, will focus on guiding growth strategies, including Ayurveda hospital expansion and OTC Ayurveda product launches.

Corporate Governance and Financial Decisions

The Board made several other strategic decisions during its August meeting:

These developments indicate the company's commitment to strengthening its operational framework while rewarding stakeholders through dividend distributions and employee participation schemes.

Strategic Positioning

The combination of regulatory approvals for the ESOP scheme, strategic leadership appointments, and governance enhancements suggests Jeena Sikho Lifecare is positioning itself for expansion in the Ayurveda and wellness sector. The company's focus on employee retention through stock options and operational efficiency through experienced leadership appointments demonstrates a comprehensive approach to sustainable growth.